BPC-157

Mechanism of action: Promotion of angiogenesis; Nitric oxide modulation; Fibroblast migration; Collagen synthesis; Tendon and ligament repair; Anti-inflammatory signaling; (These mechanisms remain incompletely established in humans.)

Proposed indications: Tendon healing; Ligament repair; Muscle injury recovery; Gastrointestinal ulcer healing; Inflammatory bowel disease; Wound healing

Commonly reported by peptide clinics†: 200-500 mcg once or twice daily, subcutaneous

Peptide clinics and compounding pharmacies commonly report 200-500 mcg once or twice daily by subcutaneous injection, often near the site of injury for localized use. Human evidence is essentially limited to animal models, plus one extremely small 2025 pilot study (2 participants, intravenous route) that does not establish efficacy or a real dosing regimen.

†Reported by peptide clinics and compounding pharmacies -- not derived from human clinical trials. Not an individualized recommendation. Actual use should be supervised by a qualified provider.

Typical clinical dosing schedule: No established clinical dosing because BPC-157 is not an approved therapeutic agent. Published human dosing recommendations are lacking.

Administration: Oral or subcutaneous (routes reported in research and commercial use; no approved formulation exists) — No established clinical dosing

Compare with: TB-500 (Thymosin β4 Fragment)GHK-Cu (Copper Tripeptide-1)

An "emerging / limited evidence" rating means rigorous research hasn't caught up yet -- not that this peptide doesn't work. Many peptides in this category are newer or simply understudied rather than proven ineffective.

Evidence rating: ⭐☆☆☆☆ — No robust randomized human trials supporting clinical use.

Landmark trials: Sikiric and colleagues — Demonstrated improved tendon, ligament, and gastrointestinal healing in rodent models. High-quality randomized human trials are lacking.

Common side effects: Injection-site irritation, Headache, Nausea

Serious risks: Unknown long-term safety; Altered angiogenesis (theoretical concern); Unrecognized effects on tumor biology (theoretical concern); Product purity and contamination in non-regulated markets

Legal status: Not FDA-approved for human use. This is a research compound, not a medication — any use should only occur under the direction of a licensed healthcare provider, and its legal availability varies and changes frequently. Verify current status independently before considering use.

Regulatory status: Research peptide • Not FDA approved • Not approved by EMA • Not permitted by WADA in competitive sport if classified under prohibited categories depending on formulation/use

Contraindications: Unknown. Avoid use in:; Pregnancy; Active cancer; Children; Individuals with significant medical conditions outside research settings

Pregnancy & breastfeeding: Avoid.

Sikiric P, et al. (2018). Stable Gastric Pentadecapeptide BPC 157: Review. Pevec D, et al. (2010). Experimental tendon healing studies.